Mode
Text Size
Log in / Sign up
Phase 2 N=35 Randomized Treatment

Employment-Based Depot Naltrexone Clinical Trial

Opiate Dependence

Enrolled (actual)
35
Serious AEs
0.0%
Results posted
Dec 2017
Primary outcome: Primary: Percentage of Depot Naltrexone Doses Received — 42.2; 80.6 percentage of injections — p==0.008

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
employment-based reinforcement (Combination_product)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Johns Hopkins University
Primary completion
May 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Depot Naltrexone Doses Received
42.2; 80.6 =0.008 sig
SECONDARY
The Time to the First Missed Dose of Depot Naltrexone
9.3; 15.5 0.0033 sig
SECONDARY
Percentage of 30-day Assessments Urine Samples Negative for Opiates
61.8; 73.6
SECONDARY
Percentage of Monday, Wednesday, Friday Urine Samples Negative for Opiates
51.6; 72.0
SECONDARY
Percentage of 30-day Assessments Urine Samples Negative for Cocaine
54.4; 55.6 0.939
SECONDARY
Percentage of Monday, Wednesday, Friday Urine Samples Negative for Cocaine
48.9; 55.6
SECONDARY
HIV Risk Behaviors
5; 5 0.959

Summary

The purpose of this study is to determine whether employment-based naltrexone treatment proves effective in promoting depot naltrexone adherence and drug abstinence.

Eligibility Criteria

Individuals were eligible if they:

  • met the Diagnostic and Statistical Manual of Mental Disorders, 4th. Edition (DSM-IV) criteria for opioid dependence,
  • reported using heroin on at least 21 of the last 30 days while in community,
  • were unemployed,
  • were aged 18-65 years,
  • were medically approved for naltrexone
  • lived in or near Baltimore, MD.

Individuals were excluded if they

  • had current DSM-IV major Axis I disorders,
  • had current suicidal or homicidal ideation,
  • expressed interest in methadone treatment,
  • were required to use opioids for medical purposes,
  • earned more than $200 in taxable income over the previous 30 days,
  • had physical limitations that would prevent them from using a keyboard,
  • were pregnant or breastfeeding,
  • had serum aminotransferase levels more than three times over normal.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00684788). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search